Tải bản đầy đủ - 0trang
8 Native Vitamin D Supplementation and Vitamin D Analogs in CKD Children
J. Bacchetta and I.B. Salusky
Native Vitamin D Therapy
In addition to providing a substrate for the formation of calcitriol, thus indirectly
suppressing PTH levels, Ritter et al. identified that 25-D continues to directly suppress PTH synthesis even when parathyroid gland 1 alpha hydroxylase is inhibited,
thus demonstrating a direct effect of 25-D on PTH synthesis, independent of 1,25-D
. Moreover, a recent placebo-controlled randomized trial also demonstrated that
ergocalciferol was able to delay the onset of secondary hyperparathyroidism in
pediatric patients with pre-dialysis CKD . As such, native vitamin D supplementation appears to be a cornerstone of pediatric CKD-MBD management. Although
current international guidelines suggest that increased PTH levels, in face of 25-D
insufficiency/deficiency (<30 ng/ml) be first treated with native vitamin D supplementation, no ‘practical’ guidelines are provided concerning the dose (daily,
monthly, quarterly?) and the type of vitamin D (ergocalciferol or cholecalciferol)
depending on age, body weight, severity of 25-D deficiency and CKD stage. In the
future, clinical trials my focus on this rather simple but critical question.
Vitamin D Analogs
Following 25-D repletion, if hyperparathyroidism is not controlled according to
specific CKD stage, active vitamin D sterols should be initiated to help controlling
serum PTH values. However, one should keep in mind that optimal PTH levels
remain to be defined: indeed, the international KDIGO guidelines recommend PTH
levels two to nine times the upper normal limit in CKD stage V , whereas
European pediatric guidelines recommend PTH levels two to three times the upper
normal limit in CKD stage V . This threshold remains discussed, but high PTH
levels are also well known to be associated with anemia, left ventricular hypertrophy
and vascular calcifications; a recent 2013 report from the international pediatric
peritoneal dialysis (PD) registry (IPPN) proposed a PTH target between 100 and
200 pg/ml in children undergoing chronic PD , keeping in mind that it can be
difficult to propose guidelines for PTH levels since the assays can have a 30–50 %
variability across the world
In 2010, a Cochrane review emphasized the paucity of long-term data on safety
and efficacy of different active vitamin D sterols for the treatment of pediatric secondary hyperparathyroidism; however, PTH levels have been shown to decrease
similarly with all preparations . Although vitamin D sterols are currently the
mainstay of therapy for elevated PTH levels, over-suppression of PTH levels in
maintenance dialysis children may lead to adynamic bone disease, a condition associated with growth failure and cardiovascular calcifications. Active vitamin D sterols, particularly calcitriol, may also inhibit the growth plate. Taken together, these
data illustrate that active vitamin D sterols exert a positive role in controlling PTH
levels and osteitis fibrosa but, with excessive use, may result in excessive PTH
Vitamin D in Children with Chronic Kidney Disease
suppression, adynamic bone disease, growth failure, and progressive cardiovascular
calcifications but such suppression of secondary hyperparathyroidism is associated
with progressive rise of FGF23 . Since there are currently no data demonstrating
any differences on the control of secondary hyperparathyroidism or renal osteodystrophy between the various active vitamin D sterols the choice may depend on local
prescription options; and when calcitriol was compared to doxercalciferol similar
control of secondary hyperparathyroidism was obtained but doxercalciferol had a
greater degree of osteoclastic suppression.
Calcimimetics have been used in pediatric CKD, but their use remains off-label
[62–64]. As discussed above, recent clinical trials in CKD adults receiving cinacalcet or placebo have shown that cinacalcet significantly decreases FGF23 levels .
In the meantime, international pediatric clinical trials on cinacalcet in dialysis are
ongoing, and may change our daily management of pediatric ROD and CKD-MBD
in a near future. Figure 13.1 summarizes the current understanding on phosphate/
calcium metabolism in human physiology, while Fig. 13.2 summarizes the effects
of different CKD-MBD therapies on this complex pathway.
Fig. 13.1 The current understanding of calcium/phosphate metabolism regulation in human physiology. Grey arrows corresponding to an inhibiting effect; Red arrows corresponding to a stimulating effect
J. Bacchetta and I.B. Salusky
Vitamin D analogs
1-25 vitamin D
Fig. 13.2 The different effects on calcium, phosphate, FGF23 and PTH levels of the current therapies used for CKD-MBD management. (a) Effects of active vitamin D analogs and calcimimetics.
(b) Effects of calcium-based and calcium-free phosphate binders. Grey arrows corresponding to an
inhibiting effect; Red arrows corresponding to a stimulating effect. It is noteworthy that not all the
Ca-free binders reduce FGF23; for example, lanthanum can reduce FGF23 levels mainly when
used with dietary restriction
Vitamin D in Children with Chronic Kidney Disease
Vitamin D After Pediatric Renal Transplantation
Vitamin D deficiency remains an important problem after renal transplantation
[65, 66]; in this context, regular vitamin D supplementation may serve as a potentially modifiable factor. Indeed, vitamin D plays an important role for bone quality
after renal transplantation, but it also has critical roles in immunity (through a natural inhibition of the mTor signalling) . In that setting, low 25D levels before
transplantation have also been shown to be associated with an increased risk of
cancer after transplantation whilst low 25(OH)D levels have been linked with an
increased risk of delayed graft function [68, 69].
Recent research has confirmed that 25(OH)D has plenty of metabolic actions,
including beneficial effects on bone, vessels, inflammation, defense against infection and muscle function, all being frequent conditions in pediatric CKD patients;
however the impact of vitamin D therapy on each of these specific conditions remain
to be defined. Recently, normal 25(OH)D levels have been shown to be associated
with less proteinuria and to attenuate renal failure progression in 167 CKD children
(median GFR 51 mL/min per 1.73 m2) from the ESCAPE trial. In this study, renal
survival increased by 8.2 % per 10 nmol/L increase in 25-D levels, independently of
GFR, proteinuria, blood pressure and FGF23 levels; the threshold for observing
such an effect was 50 nmol/L .
Although there are no large randomized controlled trial on the effects on nutritional vitamin D in CKD patients (and especially in children!), and since vitamin D
should be considered as a hormone, it seems prudent to restore sufficient serum
levels. Over dosage is quite uncommon despite extensive administration, and could
be easily monitored by serum calcium and 25(OH)D levels, a routine measure in
pediatric CKD. In the future, international and large clinical trials should provide
not also practical guidelines for 25-D supplementation but also evidence for global
beneficial effects of this non-expensive and well-tolerated drug.
Disclosure of Interest JB: research grants from Amgen, Sandoz, Novartis and Crinex; consulting
fees from Amgen, Genzyme, Otsuka and Pfizer.
IBS: Amgen, OPKO, Abbvie and Sanofi
1. Bacchetta J, Harambat J, Cochat P, Salusky IB, Wesseling-Perry K. The consequences of
chronic kidney disease on bone metabolism and growth in children. Nephrol Dial Transplant.
J. Bacchetta and I.B. Salusky
2. Denburg MR, Kalkwarf HJ, de Boer IH, Hewison M, Shults J, Zemel BS, et al. Vitamin D
bioavailability and catabolism in pediatric chronic kidney disease. Pediatr Nephrol.
3. Menon S, Valentini RP, Hidalgo G, Peschansky L, Mattoo TK. Vitamin D insufficiency and
hyperparathyroidism in children with chronic kidney disease. Pediatr Nephrol. 2008;23:1831–6.
4. Belostotsky V, Mughal MZ, Berry JL, Webb NJ. Vitamin D deficiency in children with renal
disease. Arch Dis Child. 2008;93:959–62.
5. Bacchetta J, Dubourg L, Harambat J, Ranchin B, Abou-Jaoude P, Arnaud S, et al. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab. 2010;95:1741–8.
6. Cho HY, Hyun HS, Kang HG, Ha IS, Cheong HI. Prevalence of 25(OH) vitamin D insufficiency and deficiency in pediatric patients on chronic dialysis. Perit Dial Int. 2013;33:398–404.
7. Kumar J, McDermott K, Abraham AG, Friedman LA, Johnson VL, Kaskel FJ, et al. Prevalence
and correlates of 25-hydroxyvitamin D deficiency in the Chronic Kidney Disease in Children
(CKiD) cohort. Pediatr Nephrol. 2016;31:121–9.
8. Shroff R, Wan M, Gullett A, Ledermann S, Shute R, Knott C, et al. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized
trial. Clin J Am Soc Nephrol. 2012;7:216–23.
9. Bacchetta J, Chun RF, Gales B, Zaritsky JJ, Leroy S, Wesseling-Perry K, et al. Antibacterial
responses by peritoneal macrophages are enhanced following vitamin D supplementation.
PLoS One. 2014;9:e116530.
10. Bacchetta J, Zaritsky JJ, Sea JL, Chun RF, Lisse TS, Zavala K, et al. Suppression of ironregulatory hepcidin by vitamin D. J Am Soc Nephrol. 2014;25:564–72.
11. Rianthavorn P, Boonyapapong P. Ergocalciferol decreases erythropoietin resistance in children
with chronic kidney disease stage 5. Pediatr Nephrol. 2013;28:1261–6.
12. Mahesh S, Kaskel F. Growth hormone axis in chronic kidney disease. Pediatr Nephrol.
13. Salusky IB, Goodman WG. Growth hormone and calcitriol as modifiers of bone formation in
renal osteodystrophy. Kidney Int. 1995;48:657–65.
14. Kuizon BD, Salusky IB. Growth retardation in children with chronic renal failure. J Bone
Miner Res. 1999;14:1680–90.
15. Naja RP, Dardenne O, Arabian A, St Arnaud R. Chondrocyte-specific modulation of Cyp27b1
expression supports a role for local synthesis of 1,25-dihydroxyvitamin D3 in growth plate
development. Endocrinology. 2009;150:4024–32.
16. Priemel M, von Domarus C, Klatte TO, Kessler S, Schlie J, Meier S, et al. Bone mineralization
defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and
circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res. 2010;25:305–12.
17. Scheimberg I, Perry L. Does low vitamin D have a role in pediatric morbidity and mortality?
An observational study of vitamin D in a cohort of 52 postmortem examinations. Pediatr Dev
18. Anderson PH, Lam NN, Turner AG, Davey RA, Kogawa M, Atkins GJ, et al. The pleiotropic
effects of vitamin D in bone. J Steroid Biochem Mol Biol. 2013;136:190–4.
19. Owen TA, Aronow MS, Barone LM, Bettencourt B, Stein GS, Lian JB. Pleiotropic effects of
vitamin D on osteoblast gene expression are related to the proliferative and differentiated state
of the bone cell phenotype: dependency upon basal levels of gene expression, duration of
exposure, and bone matrix competency in normal rat osteoblast cultures. Endocrinology.
20. Allard L, Demoncheaux N, Machuca-Gayet I, Georgess D, Coury-Lucas F, Jurdic P, et al.
Biphasic effects of vitamin D and FGF23 on human osteoclast biology. Calcif Tissue Int.
21. Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, et al.
Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin
D-induced inhibition of bone mineralization. J Clin Invest. 2012;122:1803–15.
Vitamin D in Children with Chronic Kidney Disease
22. Heidbreder E, Naujoks H, Brosa U, Schramm L. The calcium-parathyroid hormone regulation
in chronic renal failure investigation of its dynamic secretion pattern. Horm Metab Res.
23. Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol.
24. Harambat J, Cochat P. Growth after renal transplantation. Pediatr Nephrol. 2009;24:
25. Sanchez CP, Salusky IB, Kuizon BD, Abdella P, Juppner H, Goodman WG. Growth of long
bones in renal failure: roles of hyperparathyroidism, growth hormone and calcitriol. Kidney
26. Kuizon BD, Goodman WG, Juppner H, Boechat I, Nelson P, Gales B, et al. Diminished linear
growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int.
27. Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, et al. Calcitriol and
doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone,
and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int.
28. Groothoff JW, Offringa M, Van Eck-Smit BL, Gruppen MP, Van De Kar NJ, Wolff ED, et al.
Severe bone disease and low bone mineral density after juvenile renal failure. Kidney Int.
29. Denburg MR, Kumar J, Jemielita T, Brooks ER, Skversky A, Portale AA, et al. Fracture burden and risk factors in childhood CKD: results from the CKiD cohort study. J Am Soc Nephrol.
30. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl
J Med. 2000;342(20):1478–83.
31. Hernandez JD, Wesseling K, Pereira R, Gales B, Harrison R, Salusky IB. Technical approach
to iliac crest biopsy. Clin J Am Soc Nephrol. 2008;3:S164–9.
32. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease:
Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945–53.
33. Bakkaloglu SA, Wesseling-Perry K, Pereira RC, Gales B, Wang HJ, Elashoff RM, et al. Value
of the new bone classification system in pediatric renal osteodystrophy. Clin J Am Soc Nephrol.
34. Bacchetta J, Wesseling-Perry K, Kuizon B, Pereira RC, Gales B, Wang HJ, et al. The skeletal
consequences of growth hormone therapy in dialyzed children: a randomized trial. Clin J Am
Soc Nephrol. 2013;8:824–32.
35. Pereira RC, Juppner H, Gales B, Salusky IB, Wesseling-Perry K. Osteocytic protein expression response to doxercalciferol therapy in pediatric dialysis patients. PLoS One.
36. Bacchetta J, Salusky IB. Evaluation of hypophosphatemia: lessons from patients with genetic
disorders. Am J Kidney Dis. 2012;59:152–9.
37. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393–408.
38. Bacchetta J, Sea JL, Chun RF, Lisse TS, Wesseling-Perry K, Gales B, et al. Fibroblast growth
factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes.
J Bone Miner Res. 2013;28:46–55.
39. Andrukhova O, Smorodchenko A, Egerbacher M, Streicher C, Zeitz U, Goetz R, et al. FGF23
promotes renal calcium reabsorption through the TRPV5 channel. EMBO. 2014;33:
40. Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B, et al. FGF23 regulates renal sodium handling and blood pressure. EMBO. 2014;6:744–59.
J. Bacchetta and I.B. Salusky
41. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, et al. Iron deficiency drives an
autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A. 2011;108(46):E1146–55.
42. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast
growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med.
43. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, et al. Fibroblast growth
factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate
Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18:2600–8.
44. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Fibroblast growth factor 23
and risks of mortality and end-stage renal disease in patients with chronic kidney disease.
45. Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK. Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO
study. J Am Soc Nephrol. 2016;27:227–37.
46. Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry
K. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.
47. Khouzam NM, Wesseling-Perry K, Salusky IB. The role of bone in CKD-mediated mineral
and vascular disease. Pediatr Nephrol. 2015;30:1379–88.
48. Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, et al. FGF23 neutralization
improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.
J Clin Invest. 2012;122:2543–53.
49. Bellasi A, Reiner M, Petavy F, Goodman W, Floege J, Raggi P. Presence of valvular calcification predicts the response to cinacalcet: data from the ADVANCE study. J Heart Valve Dis.
50. Investigators ET, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, et al. Effect
of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med.
51. Kubo Y, Sterling LR, Parfrey PS, Gill K, Mahaffey KW, Gioni I, et al. Assessing the treatment
effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.
Pharm Stat. 2015;14:242–51.
52. Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, et al. Cinacalcet,
fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation.
53. Isakova T, Ix JH, Sprague SM, Raphael KL, Fried L, Gassman JJ, et al. Rationale and
approaches to phosphate and fibroblast growth factor 23 reduction in CKD. J Am Soc Nephrol.
54. Olauson H, Vervloet MG, Cozzolino M, Massy ZA, Urena Torres P, Larsson TE. New insights
into the FGF23-Klotho axis. Semin Nephrol. 2014;34:586–97.
55. Fu H, Liu Y. Loss of Klotho in CKD breaks one’s heart. J Am Soc Nephrol. 2015;26:2305–7.
56. Xie J, Yoon J, An SW, Kuro-o M, Huang CL. Soluble Klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate. J Am Soc Nephrol.
57. Yang K, Wang C, Nie L, Zhao X, Gu J, Guan X, et al. Klotho protects against indoxyl sulphateinduced myocardial hypertrophy. J Am Soc Nephrol. 2015;26:2434–46.
58. Ritter CS, Brown AJ. Direct suppression of Pth gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptor. J Mol Endocrinol.
59. Klaus G, Watson A, Edefonti A, Fischbach M, Ronnholm K, Schaefer F, et al. Prevention and
treatment of renal osteodystrophy in children on chronic renal failure: European guidelines.
Pediatr Nephrol. 2006;21:151–9.
Vitamin D in Children with Chronic Kidney Disease
60. Haffner D, Schaefer F. Searching the optimal PTH target range in children undergoing peritoneal dialysis: new insights from international cohort studies. Pediatr Nephrol. 2013;28:
61. Geary DF, Hodson EM, Craig JC. Interventions for bone disease in children with chronic kidney disease. Cochrane. 2010;(1):CD008327.
62. Bacchetta J, Plotton I, Ranchin B, Vial T, Nicolino M, Morel Y, et al. Precocious puberty and
unlicensed paediatric drugs for severe hyperparathyroidism. Nephrol Dial Transplant.
63. Silverstein DM, Kher KK, Moudgil A, Khurana M, Wilcox J, Moylan K. Cinacalcet is efficacious in pediatric dialysis patients. Pediatr Nephrol. 2008;23:1817–22.
64. Platt C, Inward C, McGraw M, Dudley J, Tizard J, Burren C, et al. Middle-term use of
Cinacalcet in paediatric dialysis patients. Pediatr Nephrol. 2010;25:143–8.
65. Bacchetta J, Ranchin B, Demede D, Allard L. The consequences of pediatric renal transplantation on bone metabolism and growth. Curr Opin Organ Transplant. 2013;18:555–62.
66. Ebbert K, Chow J, Krempien J, Matsuda-Abedini M, Dionne J. Vitamin D insufficiency and
deficiency in pediatric renal transplant recipients. Pediatr Transplant. 2015;19:492–8.
67. Lisse TS, Liu T, Irmler M, Beckers J, Chen H, Adams JS, et al. Gene targeting by the vitamin
D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling.
68. Ducloux D, Courivaud C, Bamoulid J, Kazory A, Dumoulin G, Chalopin JM. Pretransplant
serum vitamin D levels and risk of cancer after renal transplantation. Transplantation.
69. Falkiewicz K, Boratynska M, Speichert-Bidzinska B, Magott-Procelewska M, Biecek P,
Patrzalek D, et al. 1,25-dihydroxyvitamin D deficiency predicts poorer outcome after renal
transplantation. Transplant Proc. 2009;41:3002–5.
70. Shroff R, Aitkenhead H, Costa N, Trivelli A, Litwin M, Picca S, et al. Normal 25-hydroxyvitamin
D levels are associated with less proteinuria and attenuate renal failure progression in children
with CKD. J Am Soc Nephrol. 2016;27:314–22.
Non-classical Effects of Vitamin D
Vitamin D and Progression of Renal Failure
Marc De Broe
Abstract In addition to his widely recognized endocrine effects on the calcium,
phosphate, PTH metabolism, vitamin D has many other pleiotropic effects on the
vascular function, blood pressure, proteinuria, insulin resistance, lipid metabolism,
inflammation, immunity which all may play a role in the progression of renal failure.
Angiotensin-converting enzyme inhibitors (ACEi) for renin-angiotensin-aldosterone
system (RAAS) blockade are routinely used to slow CKD progression. Natural vitamin D and active vitamin D analogs may further reduce proteinuria in CKD patients
in addition to these current treatment regimens. The inverse correlation of blood
pressure and vitamin D plasma levels as well as promising data from small intervention studies of vitamin D supplementation provide a rationale for well performed
RCT addressing efficacy and safety of vitamin D in hypertension/cardiovascular
diseases. Unfortunately, up to now three RCT have not been able to support this.
Determination of the optimal vitamin D analogue and its optimal dosage in case
of protection or slowing down the development of vascular calcifications remains to
be investigated in depth in pre-clinical and clinical conditions. Vitamin D supplementation may lead to a small but significant improvement in mortality but did not
appear to prevent the development of diabetes in the largest clinical trial to date.
Effects of Vitamin D on renal fibrosis and slowing down/preventing progressive
renal damage has been investigated thoroughly in vitro, in vivo and in humans but
currently limited to a promising item. The increase in serum creatinine observed
during several studies is not attributable to a decrease of the glomerular filtration
rate but on the increased creatinine generation, an anabolic effect of vitamin
D. Natural vitamin D and active vitamin D preparations are among the few reasonable and evident candidates to be tested in a multicenter, prospective RCT as a
potential protector of the failing kidney in patients with CKD 3 and 4.
Keywords Chronic kidney disease • Proteinuria • Hypertension • Renin
• Angiotensin • Aldosterone • Calcium • Parathyroid hormone • Phosphate • VDR
• Inflammation • FGF23 • Randomized clinical trial (RCT)
M. De Broe, MD, PhD
University Antwerpen, Antwerp, Belgium
© Springer International Publishing Switzerland 2016
P.A. Ureña Torres et al. (eds.), Vitamin D in Chronic Kidney Disease,
M. De Broe
Patients with progressive chronic kidney disease (CKD) develop phosphate
retention becoming apparent in the serum when CKD stage 3–4 is reached.
Indeed FGF23 is secreted by osteocytes at early stage of renal insufficiency and
because of his potent phosphaturic effect (by decreasing the brush-border abundance of the sodium phosphate (NaPi2a co-transporter channels) is able to control this phosphate retention at least up to estimated glomerular filtration rate
(eGFR) of 50 ml/min/1.73 m2. Concomitantly FGF23 inhibit synthesis of active
vitamin D (calcitriol), inducing a decrease of gastro-intestinal absorption of calcium and hence less inhibitory effect of PTH synthesis at the level of the PTH
Klotho expression, an essential co-factor for the phosphatonin FGF23 signaling, is reduced in the failing kidney also at early stages. This reduced klotho levels
results in relative FGF23 resistance/less effective elevated levels of FGF23 in promoting renal phosphate excretion The decreased synthesis of active vitamin D,
the progressive phosphate retention inducing a relative decrease in ionized calcium (counter ion effect) stimulate PTH synthesis and secretion resulting in the
classical secondary hyperparathyroidism (SHPT) of patients with CKD stage 5
In 1978, a study published in The Lancet reported 18 patients who had advanced
CKD, and presence of renal osteodystrophy and were treated with either natural
vitamin D3 (4,000 IU/day) or 1,25-dihydroxyvitamin D (1,25(OH)2D; 1 μg/day)
along with 500 mg of calcium after a 6-month observation period . In the group
treated with 1,25(OH)2D, seven of eight patients developed hypercalcemia that
necessitated a reduction in dosage. The percentage fall in creatinine clearance was
greater during treatment than before treatment in all patients who were on
1,25(OH)2D (P < 0.01) and in seven of nine patients on vitamin D3 treatment. The
authors concluded that deterioration of renal function was a major limitation of the
clinical use of 1,25(OH)2D and vitamin D3 in non-dialyzed patients with CKD. Time
and things have changed. Currently vitamin D may be considered as one of the leading substances opening perspectives, never thought of, not only concerning his well
established favorable effects on the bone and mineral metabolism but as having the
potential to slow down the progression of CKD.
The discovery that most tissues and cells in the body have a vitamin D receptor
and that several possess the enzymatic machinery to convert the primary circulating
form of vitamin D, 25-hydroxyvitamin D, to the active form, 1,25-dihydroxyvitamin
D, has opened the way for the currently, discovered many effects of vitamin D in
almost any organ/system of the body.
The pleiotropic effects of vitamin D in CKD have been previously reviewed by
several authors [4–6]. The specific vitamin D related effects on retarding CKD progression is the main issue of this review. In this context the anti-proteinuric antihypertensive, anti-inflammatory and anti-fibrotic effects of vitamin D will be